Name: Immunome, Inc. (IMNM) Cash Flow Statement
Creator: FinSpry

Immunome Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Immunome, Inc. (IMNM) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-292.96	-106.81	-36.90	-24.71	-17.80
Depreciation & Amortization	2.10	0.77	0.63	0.76	0.80
Stock Based Compensation	15.75	6.22	5.33	3.45	0.62
Change in Working Capital	14.87	11.23	2.24	2.78	-1.91
Change in Accounts Payable	9.53	-0.61	-0.68	1.78	0.50
Change in Other Working Capital	152.34	-3.38	2.92	1.00	-1.71
Other Operating Activities	152.34	87.28	3.41	-0.50	6.82
Net Cash from Operating Activities	-110.79	-7.57	-28.69	-18.23	-12.13
Investing Activities
Capital Expenditures	-53.51	0.83	-0.25	-0.08	0.59
Acquisitions	0.00	9.28	0.00	0.00	0.00
Purchases of Investments	-186.56	-38.93	0.00	0.00	0.00
Sales/Maturities of Investments	155.00	-38.93	0.00	0.00	0.00
Other Investing Activities	-46.34	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	-85.06	-30.48	-0.25	-0.08	-0.59
Financing Activities
Debt Repayment	0.00	0.00	0.00	-0.11	0.00
Common Stock Issued	250.00	0.41	0.03	28.66	44.85
Other Financing Activities	-15.23	-9.00	0.00	-0.78	-0.45
Net Cash from Financing Activities	240.53	116.41	0.03	27.77	49.94
Summary
Net Change in Cash	44.67	78.36	-28.91	9.46	37.22
Cash at Beginning of Period	98.78	20.42	49.33	39.87	2.64
Cash at End of Period	143.45	-47.01	20.42	49.33	39.87
Free Cash Flow	-164.30	-8.40	-28.94	-18.31	-12.72
Supplemental Disclosures
Interest Paid	0.00	0.00	0.00	0.01	0.03